Key result
Valvular heart disease affects up to 30%-40% of dialysis patients, presenting significant management challenges due to high complication risks with surgical and transcatheter interventions.
Highlights the high prevalence and morbimortality burden of valvular heart disease in dialysis patients, emphasizing the need for optimal management strategies.
Valvular heart disease (VHD) is highly prevalent among dialysis patients, affecting up to 30%–40% of the population. Aortic and mitral valves are the most frequently affected and commonly lead to valvular stenosis and regurgitation. Although it is well established that VHD is associated with a high morbimortality burden, the optimal management strategy remains unclear, and treatment options are limited due to the high risk of complications and mortality after surgical and transcatheter interventions. In this issue of Clinical Kidney Journal, Elewa et al. provide new evidence in this field by reporting the prevalence and associated outcomes of VHD in patients with kidney failure on renal replacement therapy.
No takes yet. Share an insight, caveat, or question.
Espriella et al. (2023) conducted an editorial in Valvular heart disease in patients on kidney replacement therapy. Valvular heart disease affects up to 30%-40% of dialysis patients, presenting significant management challenges due to high complication risks with surgical and transcatheter interventions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: